Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A randomized, double-blind, confirmatory study of VN-100 in healthy elderly volunteers
jRCT2080222443Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2014
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of VN-100 in influenza (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Seroconversion rate of hemagglutination inhibition (HI) antibody titer after first intradermal vaccination, Geometric mean titer (GMT) of hemagglutination inhibition (HI) antibody after first intradermal vaccination and 1 more. Started Mar 2014; status: completed.
02
Drugs
VN-100
03
Conditions
influenza
Beyond the preview
Go deeper on jRCT2080222443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222443.